Tag Archive for: CNS

Rare Disease Day 2024 – Call for greater awareness of X-linked adrenoleukodystrophy and cerebral adrenoleukodystrophy

/in

Barcelona, Spain and Düsseldorf, Germany – 29 February, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system disorders, reaffirm their commitment on Rare Disease Day […]

Read more

Neuraxpharm announces the first launch of BRIUMVI® (ublituximab) in Europe for the treatment of relapsing multiple sclerosis

/in

Germany is the first European country to launch ublituximab, with further launches throughout Europe to follow Only B-cell depleting therapy approved for relapsing multiple sclerosis (RMS) that is administered in a 1-hour infusion*, twice per year** Launch follows ex-US commercialisation*** agreement with TG Therapeutics announced August 2023 Barcelona and Düsseldorf – 26 February 2024 – Neuraxpharm Group […]

Read more

Update on Regulatory Review of leriglitazone in the EU

/in

A re-examination for cerebral adrenoleukodystrophy (cALD) will be requested following a negative CHMP opinion Barcelona, Spain and Düsseldorf, Germany – 26 January, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused […]

Read more

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm

/in

Decision is not due to any public health concerns regarding generic DMF products Neuraxpharm to swiftly contest this decision at the General Court of the European Union Barcelona and Düsseldorf – 20 December, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces […]

Read more

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

/in

Professor Gertsch identifies novel transport mechanism and presents new information on mode of action as part of presentation entitled ‘Identification of an Endocannabinoid Reuptake and Recycling Machinery’ Presentation forms part of 10th Gordon Research Conference on ‘Cannabinoid Function in the CNS’ held 16-21 July 2023 outside Barcelona, Spain BASEL, Switzerland – 18 July 2023 – Synendos […]

Read more